Semax 10 mg

Semax 10 mg is a research peptide supplied as lyophilized powder. Semax has been studied in Russian clinical settings for neurological applications including ischemic stroke recovery and cognitive support. In non-medical research contexts, it is investigated for potential neurotrophic effects. It is not approved by the FDA for any medical use in the United States.

Clinical literature describes Semax primarily via intranasal administration. The lyophilized powder format of Semax 10 mg requires reconstitution for research use. No standardized injectable protocol for Semax has been established in FDA-reviewed literature.

No. Post-cycle therapy is not applicable to Semax, as the peptide does not suppress endogenous testosterone production or affect hormonal axes in the manner of anabolic steroids. Semax lacks hormonal activity entirely.

Semax is a synthetic analogue of the ACTH(4–10) fragment that lacks hormonal activity but demonstrates neurotrophic properties in research. Studies suggest it may modulate BDNF and NGF expression and affect dopaminergic and serotonergic neurotransmission. Its mechanisms are not fully understood.

Onset and duration depend on the route of administration and research protocol. Clinical studies using intranasal Semax have reported effects within days to weeks, but these findings are from specific study designs and do not directly translate to reconstituted lyophilized powder research.

No. As of 2026, Semax is not FDA-approved for any indication in the United States. The FDA has evaluated Semax-related bulk drug substances and identified insufficient clinical information to characterize their safety profile for compounded use.

Semax and Selank are both synthetic peptides studied for neurological effects, but they derive from different molecular origins. Semax is an ACTH(4–10) analogue, while Selank is a synthetic analogue of tuftsin. Both are available as research peptides from Peptide Hubs.

Semax and BPC 157 have entirely different structures and research profiles. Semax is a heptapeptide studied for neurotrophic effects, while BPC 157 is a pentadecapeptide studied primarily for tissue repair mechanisms. They are not comparable in mechanism or application.

A 10 mg vial of Semax is a research-scale quantity. Clinical studies have typically used microgram doses (300–900 mcg per day intranasally). The 10 mg vial provides sufficient material for multiple reconstituted aliquots in laboratory research settings.

Semax 10 mg by Peptide Hubs is labeled at 10 mg per vial. The product is supplied as lyophilized powder in a 2 mL vial.

Yes. A published laboratory report dated January 12, 2026 measured Semax 10 mg at 11.27 mg, equivalent to 112.70% of its 10 mg label claim. The complete report with batch number GASEMA12 can be viewed in the Lab Reports tab.

Lyophilized peptides are typically reconstituted with bacteriostatic water or sterile saline. The appropriate diluent volume depends on your desired concentration for research. Bacteriostatic Water is commonly used for peptide reconstitution to maintain sterility over multiple draws.